Description of Medical ServiceImmunohistochemistry (IHC) test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. The biopsy sample taken as part of a standard diagnostic process will be used for immunohistochemical testing with PD-L1. The testing would be done by a pathologist alongside other immunohistochemical tests which are done routinely.
Description of Medical ConditionRecurrent or metastatic head and neck squamous cell carcinoma. Head and neck cancer includes tumours arising from the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid and salivary glands. Individuals who have progressed following initial definitive treatment have recurrent disease and require subsequent treatment. Patient who present with metastatic disease generally receive the same therapy as those with recurrent disease following initial definitive treatment.
Reason for ApplicationNew MBS item
Medical Service TypeCo-dependent technology
Previous Application NumberNot Applicable
Application FormApplication Form (Word 552 KB)
Application Form (PDF 726 KB)
Consultation SurveyConsultation Survey (Word 508 KB)
Consultation Survey (PDF 307 KB)
PICO ConfirmationPICO Confirmation (PDF 1593 KB)
PICO Confirmation (Word 273 KB)
Public Summary DocumentPublic Summary Document (PDF 739 KB)
Public Summary Document (Word 262 KB)
Meetings for this Application
PASC12-13 April 2018
17 April 2020